Lyra Therapeutics, Inc. — Department of Health and Human Services SBIR Phase II: NHLBI
Lyra Therapeutics, Inc. — SBIR Phase II award from Department of Health and Human Services.
- Amount
- $2,997,541
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- Topic
- NHLBI
- NAICS
- —
- Place of performance
- MA
- Period
- —
Description
Aortic coarctation is a common congenital heart condition that is usually recognized during the neonatal period early after birth The usual treatment is open surgery Non surgical catheter based stent therapy is not available to treat neonatal aortic coarctation because children outgrow commercially available metallic stents Absorbable stents might revolutionize the treatment of aortic coarctation in children especially in neonates Neonates require small delivery systems for relatively large nominal diameter implants which is technically challenging No commercial alternatives are available for off label medical use There is a considerable unmet need for a purpose built absorbable scaffold stent for neonatal aortic coarctation